Redeye interviews Ultimovacs’ CEO Carlos de Sousa. They talk about the company’s recent top-line data readout for NIPU and its […]
Other News |
Press Releases
Interview in MedWatch with CMO Jens Bjørheim regarding the NIPU-trial
Note that the article is in Norwegian and unfortunately behind a payment wall “Ultimovacs om NIPU-studien: – Vi er mer […]
Biostock Article: About the NIPU study and interview with the Director of Medical Affairs at Ultimovacs, Espen Basmo Ellingsen
Ultimovacs in the fight against mesothelioma 2 June, 2023 Mesothelioma is a rare but aggressive form of cancer with limited […]
Ultimovacs Presentation at TD Cowen Healthcare Conference
CEO Carlos de Sousa and CMO Jens Bjørheim are presenting Ultimovacs at TD Cowen 43rd Annual Health Care Conference, March […]
Article published in Current Opinion in Oncology: “Therapeutic cancer vaccination against telomerase”
Therapeutic cancer vaccination against telomerase: clinical developments in melanoma Ellingsen, Espen Basmo; Bjørheim, Jens; Gaudernack, Gustav Please read the full article […]
Interview with Professor Gustav Gaudernack (CSO) in BioStock
The innovative force behind Ultimovacs’ cancer vaccine Read the article HERE
Carlos presenting at BioStock Life Science Fall Summit 2022
Carlos de Sousa, CEO of Ultimovacs, presents the company at BioStock Life Science Fall Summit 2022. BioStock Life Science Summit […]
Anne Worsøe (head of IR) talks about the Ultimovacs journey and our ambitions in this podcast episode (in Norwegian):
Anne Worsøe (Head of IR) talks about the Ultimovacs journey and our ambitions in this podcast episode (in Norwegian): Listen […]
Ultimovacs presentation held at Redeye Investor AW
See Ultimovacs’ Carlos de Sousa (CEO) presenting at Redeye Investor AW – Göteborg 20 October 2022 here
Career Opportunity: Translational Research Lead – Immune Oncology, permanent position
Location: Oslo (Ullernchausséen 64) About Ultimovacs Ultimovacs is a clinical-stage biotechnology company developing novel immunotherapies against cancer. Our lead product […]